- Home
- SHW vs GSK Comparison
SHW vs GSK Comparison
Compare SHW & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHW | GSK |
|---|---|---|
| Founded | 1866 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.2B | 95.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SHW | GSK |
|---|---|---|
| Price | $325.47 | $48.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 1 |
| Target Price | ★ $389.08 | N/A |
| AVG Volume (30 Days) | 1.8M | ★ 4.2M |
| Earning Date | 01-29-2026 | 10-29-2025 |
| Dividend Yield | 0.97% | ★ 3.43% |
| EPS Growth | 1.96 | ★ 118.57 |
| EPS | ★ 10.23 | 1.79 |
| Revenue | $23,275,600,000.00 | ★ $43,237,357,842.00 |
| Revenue This Year | $2.83 | $6.56 |
| Revenue Next Year | $5.14 | $5.13 |
| P/E Ratio | $31.89 | ★ $27.10 |
| Revenue Growth | 0.96 | ★ 2.73 |
| 52 Week Low | $308.84 | $31.72 |
| 52 Week High | $379.65 | $49.31 |
Technical Indicators
Market Signals| Indicator | SHW | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 40.66 | 57.86 |
| Support Level | $335.85 | $47.20 |
| Resistance Level | $344.80 | $49.31 |
| Average True Range (ATR) | 6.22 | 0.66 |
| MACD | -1.40 | -0.09 |
| Stochastic Oscillator | 24.57 | 74.32 |
Price Performance
Historical ComparisonAbout SHW Sherwin-Williams Company (The)
Sherwin-Williams is the largest provider of architectural paint in the United States. The company has over 5,000 stores and sells premium paint at higher price points than most competitors. Sherwin-Williams also sells paint-related products in big-box stores and provides coatings for original equipment manufacturers.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.